Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double
01:51am, Thursday, 02'nd May 2024
Sales of popular weight loss drug Wegovy more than doubled to 9.38 billion kroner.
Obesity drugmaker Novo Nordisk's Q1 profit beats forecast
01:34am, Thursday, 02'nd May 2024
Novo Nordisk posted on Thursday first-quarter operating profit above analyst forecasts, as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competi
Profit from the Panic: 3 Stocks to Pounce on When They Become Steals
01:41pm, Wednesday, 01'st May 2024
To paraphrase Rudyard Kipling, the secret to success in the stock market is to “keep your head when all about you are losing theirs.” When everyone is panicking and sending the market lower, that'
Novo Nordisk owner to invest $200 million in quantum computing startups
03:02am, Wednesday, 01'st May 2024
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , said on Wednesday it plans to invest around $200 million in quantum computing startups.
What Novo Nordisk's Ozempic Success Means for Denmark
02:14am, Wednesday, 01'st May 2024
Diabetes and obesity drugs Ozempic and Wegovy have become world famous, generating billions in sales and opening a new market for weight loss drugs. The development of semaglutide, the key ingredient
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
01:56pm, Tuesday, 30'th Apr 2024
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
01:48pm, Tuesday, 30'th Apr 2024
The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'
01:30pm, Tuesday, 30'th Apr 2024
WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting in
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
12:21pm, Tuesday, 30'th Apr 2024
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
02:35pm, Monday, 29'th Apr 2024
Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.
One dose of Novo Nordisk's Wegovy back in supply, FDA website shows
11:53am, Monday, 29'th Apr 2024
The U.S. Food and Drug Administration website showed on Monday one dose of Novo Nordisk's weight-loss drug Wegovy is available after being in short supply, while three other doses remained in limited
Forget Nvidia, These Unstoppable Stocks Are Better Buys
11:10am, Saturday, 27'th Apr 2024
Healthcare stocks can offer investors more predictable growth opportunities than artificial intelligence, where there's much more uncertainty in the long run. Eli Lilly and Novo Nordisk have top drugs
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
09:15am, Saturday, 27'th Apr 2024
Eli Lilly is the developer of GLP-1 treatments Mounjaro and Zepbound. Currently used to treat diabetes and obesity, they could have far more reach.
Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
12:00pm, Friday, 26'th Apr 2024
Novo Nordisk's weight loss drug, Wegovy, has received FDA approval for reducing the risk of major cardiovascular adverse events. Wegovy demonstrated a 20% reduction in the risk of major cardiovascular
Novo Nordisk hopes to prove Wegovy naysayers wrong
10:40am, Friday, 26'th Apr 2024
Europe's biggest company, the Danish weight loss drug kingpin Novo Nordisk (NYSE:NVO)'s upcoming results will be squarely focused on the uptake of the flagship Wegovy drug in the US. Analysts have war
